Keros Therapeutics
Develops protein therapeutics for neuromuscular disease and blood-cell disorders.
$11.03
After-hours close−0.02 (−0.18%)
At close$11.05(−1.60%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.94 | — | — |
| Aug 2026 | −$1.34 | −$1.45 | −8.2% |
| May 2026 | −$0.92 | −$1.21 | −31.5% |
| Mar 2026 | −$0.49 | −$0.86 | −75.5% |
| Nov 2025 | −$1.11 | −$0.18 | +83.8% |
The latest year is open to everyone — the 26 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Apr 2020 | |||
| Sep 2019 | |||
| Jun 2019 | |||
| Mar 2019 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 4, 2026 | −$0.94 | — | — | $14.8M | — | — |
| Aug 3, 2026 | −$1.34 | −$1.45 | −8.2% | $807.1K | — | — |
| May 14, 2026 | −$0.92 | −$1.21 | −31.5% | $1.9M | $367.0K | −81.0% |
| Mar 4, 2026 | −$0.49 | −$0.86 | −75.5% | $3.7M | $385.0K | −89.5% |
| Nov 5, 2025 | −$1.11 | −$0.18 | +83.8% | $3.7M | $14.3M | +289.4% |
The latest year is open to everyone — the 26 quarters behind it read with an account. Sign in | ||||||
| Aug 6, 2025 | ||||||
| May 6, 2025 | ||||||
| Feb 26, 2025 | ||||||
| Nov 6, 2024 | ||||||
| Aug 7, 2024 | ||||||
| May 8, 2024 | ||||||
| Feb 28, 2024 | ||||||
| Nov 6, 2023 | ||||||
| Aug 7, 2023 | ||||||
| May 4, 2023 | ||||||
| Mar 3, 2023 | ||||||
| Nov 3, 2022 | ||||||
| Aug 4, 2022 | ||||||
| May 5, 2022 | ||||||
| Mar 9, 2022 | ||||||
| Nov 4, 2021 | ||||||
| Aug 5, 2021 | ||||||
| May 6, 2021 | ||||||
| Mar 25, 2021 | ||||||
| Nov 10, 2020 | ||||||
| Aug 13, 2020 | ||||||
| May 22, 2020 | ||||||
| Apr 8, 2020 | ||||||
| Sep 30, 2019 | ||||||
| Jun 30, 2019 | ||||||
| Mar 31, 2019 | ||||||